The Life Sciences sector includes companies involved in biopharmaceuticals, medical manufacturing and distribution, and bio products.
Wildflower is a holistic wellness company headquartered in Vancouver building reputable brands and quality products that incorporate the synergistic effects of plants and their extracts.
World-Class is an innovation-driven company with a principle focus on the rapidly evolving cannabis and hemp industries. Through its subsidiaries Soma Labs Scientific Inc. and Greenmantle Products Inc., World-Class deploys and manages custom-built extraction centres utilizing its custom systems, technology, and processes to efficiently produce high-quality cannabis and hemp concentrates and end-products. In addition, through its subsidiary Pineapple Express Delivery Inc., the Company offers compliant and secure delivery of government regulated products, including medical and recreational cannabis in Ontario, Manitoba and Saskatchewan, and liquor delivery in certain jurisdictions in Saskatchewan.
WPD Pharmaceuticals is a biotechnology research and development company. The Company operates in the pharmaceuticals industry with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. The Issuer is developing drugs which were researched at institutions including MD Anderson Cancer Center, Mayo Clinic and Emory University, and has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.
XORTX Therapeutics Inc. is a biopharmaceutical company with three clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection in addition to ongoing in licensing activity relating to potential therapies for Type 2 Diabetic Nephropathy (T2DN). The Company has strong intellectual property rights and established proof of concept through independent clinical studies. XORTX is working to advance its clinical development stage products that target xanthine oxidase to inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future of patients.
XPhyto Therapeutics Corp. (“XPhyto”) is a diversified bioscience company with strategic assets and investments in the field of rapid pathogen screening systems and next generation drug delivery, as well as medical cannabis opportunities focused on emerging European markets. Through its 100% owned subsidiaries and exclusive development and commercialization agreements, XPhyto is pursuing clinical programs for the transdermal and dissolvable oral delivery of conventional and cannabis based therapeutics for neurological applications, as well as rapid dissolvable oral biosensor and lateral flow assay-based screening tests for dental health applications and high-risk pandemic threats such as COVID-19, H1N1 (swine flu) and H5N1 (avian flu).
Advertisement
Publicité
Advertisement
Publicité
